Q-omics provides the consensus-scored RRH profile across patient tissues and cancer cell-line models. RRH expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RRH is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, RRH RNA expression shows 16,773 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KICH, and THYM as cancer lineages where RRH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRH survival associations across molecular data types. RRH RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRH RNA expression–survival associations across cancer types. High RRH expression shows unfavorable associations in UCEC, but favorable associations in STAD, SKCM, READ, GBM and BRCA. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for RRH RNA expression.
This table summarizes RRH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RRH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRH shows lower tumor expression in KICH, KIRP, THCA and KIRC and higher tumor expression in COAD and HNSC. The KICH box plot shows higher RRH RNA expression in normal versus tumor tissue (log2 FC = −0.481, t-test p < 0.001).
This table shows molecular features associated with RRH in patient tissues and cancer cell lines. In patient samples, RRH shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
